Vaccine produced by French company uses inactivated Sars-CoV-2 virus and can be stored in fridge
A coronavirus vaccine based on traditional vaccine technology might be as effective as the Oxford/AstraZeneca vaccine, data suggests, offering new hope for global vaccination efforts, the Guardian reports.
Vaccines currently approved for use in the UK deliver instructions for producing the coronavirus “spike” protein to cells in order, which triggers an immune response. However, the jab produced by the French pharmaceutical company Valneva involves delivering the whole – but inactivated – Sars-CoV-2 virus.
Last month the U.K. government cancelled its contract with Valneva, which included an order for about 100m doses of the vaccine, over an alleged breach of the agreement.
Not only has it been suggested that inactivated whole-virus vaccines may result in a broader immune response, but the approach could also help to maintain protection in the face of new variants. This is because it is unlikely that mutations will crop up at the same time in multiple proteins of the virus.
The Valneva jab is also stable when stored in a standard refrigerator, making it easier to distribute than the Covid vaccines, which require shipping and storage at ultra-low temperatures.
© Copyright LaPresse